pathology-surgical-pathology-2019-posters-abstracts

allied

academies

Page 43

Journal of Clinical Pathology and Laboratory Medicine | Volume 3

July 05-06, 2019 | Paris, France

Pathology and Surgical Pathology

International Conference on

Surgical and non-surgical management and treatment of glioblastomas

Alain L Fymat

International Institute of Medicine & Science, USA

lioblastoma is the common brain tumor in adults. It

remains an unmet need in oncology. To gauge the

difficulties encountered in devising treatment lines, I will

first review the morphology of brain cancers, their different

biological types and their associated risks. It is important to

grasp how a diagnosis of a suspected such tumor could be

arrived at in both the initial and the very often recurring case,

and what are the prognoses in these several instances. I will

also detail the various treatments that have been devised

so far for primary tumors and their metastases in both

cases of monotherapies or combination therapies and for

recurring tumors after treatment. For each such therapy, the

treatment results obtained in clinical trials and other reported

practices will also be discussed and summarized. At the

outset, however, it must be recalled that the use of cytotoxic

drugs (chemotherapy) is essentially an educated trial-and-

error approach with one approved drug or a combination

of a number of such drugs. It does not rely on the deep

understanding of the tumor biology nor does it consider the

braiding of both normal and cancerous cells that is embedded

in our genome. As a result, it has historically provided little

durable benefit with tumors recurring within several months,

even in the case of more accessible tumors located outside

the brain; for brain tumors, the access is even more difficult

because of the presence of the brain protective barriers,

compounding the difficulties. More effective therapies

involving other options are required either in isolation or

more likely in combination. Of these other options, the

followingwill be considered: Surgery, conformal radiotherapy,

boron neutron therapy, intensity modulated proton beam

therapy, antiangiogenic therapy, alternating electric field

therapy, without neglecting palliative therapies. Research

conducted in these and other options will also be reviewed

to include microRNA, immunotherapy, adjuvant therapy,

gene therapy, stem cell therapy and intra-nasal drug delivery.